Chinese Developers Showcase Potentially Differentiated Weight Loss Assets At ADA

Including First-In-Class ActRIIA Antibody

Multiple Chinese firms presented at this year’s ADA meeting, with a focus on weight reduction efficacy for mostly early clinical stage assets. While limited information was given on lean mass preservation, several companies are progressing drugs and combos to address this need.

Scientists (miniature) are gathering at a conference hall for a meeting.
This year’s ADA indicated that muscle-preserving drugs developed by Chinese firms for weight management are mostly in preclinical stage currently. (Shutterstock/AI-generated)

Among Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-outs in terms of new data on self-developed assets — ecnoglutide in Phase III and the Phase I first-in-class combination therapy LAE102, respectively.

The Chinese-origin, clinical-stage drugs presented at the Chicago meeting were in a notably narrow band in terms of therapeutic targets,...

More from R&D

More from Therapy Areas

Sanofi Doubles Down On Respiratory Vaccines With Vicebio Buy

 
• By 

The French major is paying $1.15bn For the UK biotech and its bivalent candidate, VXB-241.

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results

 

The biotech company is planning for Phase III based on positive topline results from Vibrance-1 in narcolepsy type 1 and remains optimistic about type 2 disease.

After Gilead Deal, Hookipa Hangs Up Its Hat

 
• By 

The Austrian firm is delisting from the NASDAQ and closing down.